Optic Nerve and Retinal Functions With Bevacizumab
The purpose of this study is to investigate the possible affection of optic nerve and retinal functions following intravitreal bevacizumab injection in human eyes.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Electrophysiological Assessment of Optic Nerve and Retinal Functions Following Intravitreal Injection of Bevacizumab (Avastin).|
- Visual Evoked Potential and Electroretinogram [ Time Frame: 4 weeks ] [ Designated as safety issue: Yes ]VEP and ERG baseline and at 1 and 4 weeks post intravitreal injection of bevacizumab.
|Study Start Date:||January 2010|
|Study Completion Date:||July 2010|
|Primary Completion Date:||July 2010 (Final data collection date for primary outcome measure)|
Patients with choroidal neovascularization
CNV due to Age-Related Macular Degenerations and Myopia were included.
Visual Evoked Potential and Elctroretinogram
To evaluate the retinal and optic nerve functions of bevacizumab when injected intravitreal in human eyes using electrophysiological tests; Electroretinogram (ERG) and Visual Evoked Potentials (VEP). Forty five eyes of 45 patients with choroidal neovascular membrane (CNV) who were prepared for intravitreal injections of 1.25mg bevacizumab underwent baseline ERG and VEP in both eyes before, and at 1 and 4 weeks after the intravitreal injections.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01361828
|Cairo, --- Select One ---, Egypt, 11421|
|Principal Investigator:||Tamer A macky||Cairo University|